What is Hexagon Bio?
Hexagon Bio operates at the intersection of genomics, automation, and computational biology. The company specializes in identifying evolutionarily refined small molecules directly from fungal genomes, which are then developed into potent therapeutics to address complex human diseases. By utilizing a highly interdisciplinary platform, Hexagon Bio effectively bridges the gap between natural product evolution and modern drug discovery, creating a scalable pipeline of candidates that traditional methods often overlook. This technological edge allows the firm to maintain a competitive advantage in the rapidly evolving biotechnology landscape, where data-driven insights are increasingly critical for successful drug development.
How much funding has Hexagon Bio raised?
Hexagon Bio has raised a total of $185.3M across 3 funding rounds:
Other Financing Round
$61M
Series A
$47M
Series B
$77.3M
Other Financing Round (2021): $61M with participation from Two Sigma Ventures, SoftBank Group, Nextech Invest, 8VC, The Column Group, and Casdin Capital
Series A (2022): $47M led by The Column Group, 8VC, and Two Sigma Ventures
Series B (2023): $77.3M supported by The Column Group, Two Sigma Ventures, NexTech, and 8VC
Key Investors in Hexagon Bio
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, employing an edge-to-edge investment model that supports companies from inception to exit.
8VC
8VC is a leading technology investment firm that backs visionary teams and industry-transforming companies, with a specific focus on smart enterprise platforms and Bio-IT.
Two Sigma Ventures
Two Sigma Ventures is an early-stage venture capital firm that invests in transformative companies leveraging information growth, computing power, and data-driven innovation.
What's next for Hexagon Bio?
With the infusion of this recent capital, Hexagon Bio is well-positioned to accelerate its research and development initiatives, moving its lead candidates closer to clinical validation. The company's strategic roadmap focuses on expanding its proprietary platform's capabilities, enhancing its automated screening processes, and deepening its understanding of protein-target interactions. As the firm transitions into more advanced stages of development, the focus will likely shift toward establishing strategic partnerships and scaling its internal pipeline to address high-unmet-need therapeutic areas. The continued support from its investor syndicate provides the necessary resources to navigate the complexities of the drug development lifecycle and achieve long-term commercial viability.
See full Hexagon Bio company page
